Stevanato Group Secures €130 Million ESG-Linked Financing From BNL BNP Paribas and Cassa Depositi e Prestiti to Support Sustainable Global Growth
Retrieved on:
Wednesday, March 8, 2023
Biotechnology, Pharmaceutical, Environmental, Social and Governance (ESG), Health, Packaging, Professional Services, Manufacturing, Other Health, BNL, NYSE, BNP Paribas, Enterprise, BNL BNP Paribas headquarters, Waste management, Partnership, Employment, Entrepreneurship, ESG, Investment, Financial institution, Development, Stevanato Group, BNP, Bank, CDP, Renewable energy, Security (finance)
Stevanato Group S.p.A. (NYSE: STVN), a global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries, today announced two separate agreements with BNL BNP Paribas and Cassa Depositi e Prestiti Group (CDP) to obtain ESG-linked funds to support its ongoing global expansion.
Key Points:
- Stevanato Group S.p.A. (NYSE: STVN), a global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries, today announced two separate agreements with BNL BNP Paribas and Cassa Depositi e Prestiti Group (CDP) to obtain ESG-linked funds to support its ongoing global expansion.
- BNL BNP Paribas is participating in the financing with a contribution of €70 million which is tied to two ESG-related objectives including increasing the Company’s renewable-based energy and waste management improvements.
- Together, the financing agreements help solidify the Company's commitment to organic and sustainable growth.
- With this added visibility, we see elevated demand in the coming years,” commented Marco Dal Lago, Chief Financial Officer of Stevanato Group.